Navigation Links
Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting
Date:4/28/2009

of the side effects," said Paul Pockros, M.D., division head of gastroenterology and hepatology at Scripps Clinic and the principal investigator of the study. "A safe, easily tolerated alternative such as AST-120 would be of great benefit in the management of these patients."

The ASTUTE Trial ("AST-120 Use for the Treatment of Hepatic Encephalopathy") is a Phase 2 multi-site, randomized, double-blind, placebo-controlled 8-week study in up to 150 patients with MHE. Patients will be evaluated on neurocognitive improvement at the end of the study, defined as the change in the global summary score of the RBANS or Repeatable Battery for the Assessment of Neuropsychological Status.

"The ASTUTE trial will use a battery of neuropsychometric tests to assess the efficacy of AST-120 in an MHE population," said Scott Harris, M.D., Ocera's chief medical officer, "Up to 60 percent of patients with cirrhosis have MHE and impaired neurocognitive function, a condition for which no drugs are approved."

About AST-120

AST-120 is a novel microspherical carbon adsorbent with a selective adsorption profile for a variety of unwanted substances in the digestive tract. These substances may be responsible for a number of conditions, including Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), and pouchitis. They include ammonia, indoles (serotonin, octopamine), histamine, secondary bile acids, advanced glycation endproducts (AGE), and certain bacterial toxins. Ocera licensed the compound from the Kureha Corporation (Japan) in 2005.

About Ocera Therapeutics, Inc.

Ocera Therapeutics, based in San Diego, California, USA, is a privately held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic liver diseases and a broad range of gastrointestinal disorders. In addition to AST-120, Ocera is developing OCR-002 in he
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
2. Ocera Therapeutics Closes $35.5 Million Series C Financing
3. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
4. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
5. Dr Stephan Rietiker Joins BioCeramic Therapeutics
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. ... announces that a new market ... its catalogue: Whole ... (Systems, Kits (Library Preparation, Target ... Technology (Sequencing by Synthesis), by ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a ... SoundConnect to support their communication needs with ... web conferencing platform GlobalMeet powered by SoundConnect. The ... SoundConnect delivers award winning “results driven” business ... will be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014 Rhythm, ... diseases and genetic deficiencies that result in metabolic disorders, ... on Form S-1 with the U.S. Securities and Exchange ... of shares of its common stock. The number of ... the offering have not yet been determined. ...
Breaking Biology Technology:Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... , , Additions to the Human Protein ... 6,100 antibodies powered by Atlas Antibodies , , ST. ... today announced the release of over 2,300 antibody additions to ... www.sigma.com/prestige ), bringing the total number of highly ...
... Austria, June 23 MIG Fonds and AFFiRiS AG are,this ... Award,competition, hosted by the industry magazine Boerse-Express and Junge,Industrie. The ... the Austrian biotechnology company as well as a euro,430 million ... Last Tuesday MIG Fonds and AFFiRiS AG were awarded ...
... June 22 Trubion Pharmaceuticals, Inc. (Nasdaq: ... of Wyeth (NYSE: WYE ), has exercised ... with Trubion to extend the research period for an ... terms of the research period extension, Wyeth,s obligations to ...
Cached Biology Technology:Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 2Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 3Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 4AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 3Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced the ... Genetics from October 18 22, 2014 in San ... the entry of students, post doctorates and scientists from ... community and to encourage the participation of young scientists ... year MARC conferred 16 awards totaling $29,600., The FASEB ...
(Date:8/28/2014)... peer groups and clinicians is critical to the ... University of Georgia research. , A qualitative study ... determined that role models for successful breastfeeding help ... , "Mothers who received that support are more ... co-author Alex Anderson, an associate professor in the ...
(Date:8/28/2014)... to Research Careers) Program has announced the travel ... Medicine,s Conference on Integrative Physiology of Exercise from ... awards are meant to promote the entry of ... into the mainstream of the basic science community ... at the American College of Sports Medicine,s Conference ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2
... conditions leading to heart attacks and strokes are treated ... or lung, but now turn out to involve some ... This in turn provides clues to more effective therapies ... in these distinct fields to come together. The seeds ...
... DC Although Americans are becoming increasingly aware of ... A in some baby bottles and lead in some ... with personal chemical exposure and related adverse health effects, ... Journal of Health and Social Behavior . ...
... the Nov. 20 edition of Heredity could ... evolution of separate sexes, a theory that holds that ... stages are not completely understood because the majority of ... state too long ago for scientists to observe the ...
Cached Biology News:Mechanisms of cardiovascular disease and cancer give clues to new therapies 2Mechanisms of cardiovascular disease and cancer give clues to new therapies 3Pollution at home lurks unrecognized, instead attributed to large-scale environmental disasters 2Two from one: Pitt research maps out evolution of genders from hermaphroditic ancestors 2
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: